BRISBANE, Calif. , Sept. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company pioneering the development of advanced

加利福尼亚州布里斯班，2026年9月11日（环球社讯）——Tempest Therapeutics, Inc.（纳斯达克股票代码：TPST）（“公司”），一家处于临床阶段的生物技术公司，致力于开创性地开发先进

in vivo

体内

CAR-T therapies for cancer and autoimmune disease, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,105,591 shares of common stock (or pre-funded warrant in lieu thereof), series C warrants to purchase up to 3,105,591 shares of common stock and series D warrants to purchase up to 3,105,591 shares of common stock, at a combined purchase price of $0.805 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement.

该公司专注于癌症和自身免疫性疾病的CAR-T疗法，今日宣布已签订最终协议，以每股普通股（或替代的预融资权证）0.805美元的合并购买价格，通过私募配售方式买卖合计3,105,591股普通股（或替代的预融资权证），以及最多可购买3,105,591股普通股的C系列权证和最多可购买3,105,591股普通股的D系列权证。

The series C warrants and the series D warrants will have an exercise price of $0.805 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants (the “Stockholder Approval Date”). The series C warrants will expire six years from the later of the Stockholder Approval Date and the Effectiveness Date (as defined below) and the series D warrants will expire three years from the later of the Stockholder Approval Date and the Effectiveness Date.

C系列认股权证和D系列认股权证的行权价格为每股0.805美元，并自股东批准因行使认股权证而可发行股份的生效日期（“股东批准日”）起可行使。C系列认股权证将在股东批准日与下文定义的“生效日”两者中较晚之日起六年后到期，D系列认股权证将在股东批准日与生效日两者中较晚之日起三年后到期。

The private placement is expected to close on or about September 14, 2026, subject to the satisfaction of customary closing conditions..

预计此次私募配售将于2026年9月14日或前后完成，但须满足惯常的交割条件。

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

H.C. Wainwright & Co. 担任本次发行的独家配售代理。

The gross proceeds from the offering are expected to be approximately $2.5 million, prior to deducting placement agent fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the series C warrants and the series D warrants, if fully exercised on a cash basis, will be approximately $5 million.

本次发行的总收益预计约为250万美元，该金额未扣除配售代理费用及公司应支付的其他发行费用。若C系列认股权证和D系列认股权证全部以现金方式行权，公司由此获得的潜在额外总收益将约为500万美元。

No assurance can be given that any of the warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the warrants. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes..

无法保证任何认股权证将被行使，也无法保证公司将从认股权证的行使中获得现金收益。公司打算将本次发行的净收益用于营运资金和其他一般公司用途。

The securities described above are being offered in a private placement exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) thereof and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws.

上述证券正根据经修订的《1933年证券法》（以下简称“《证券法》”）第4(a)(2)条和/或据此颁布的D条例，以豁免注册的私募配售方式发行；该等证券以及认股权证项下的基础普通股股份均未根据《证券法》或适用的州证券法律进行注册。

Accordingly, the securities issued in the private placement and shares of common stock underlying the warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

因此，除非依据生效的注册声明或适用《证券法》及相应州证券法律中关于注册要求的豁免规定，否则不得在美国要约或出售私募发行的证券以及权证所对应的普通股股份。

Pursuant to a registration rights agreement, the Company has agreed to file a registration statement covering the resale of the common stock (or the shares of common stock issuable upon exercise of the pre-funded warrant in lieu thereof) issued in the private placement and the shares of common stock issuable upon exercise of the warrants issued in the private placement (the date of effectiveness of such registration statement, the “Effectiveness Date”)..

根据一项注册权协议，公司已同意提交一份注册声明，涵盖在私募中发行的普通股（或可代替该等普通股而在行使预融资权证时可发行的普通股股份）的转售，以及在私募中发行的权证行使时可发行的普通股股份（该注册声明生效之日为“生效日”）。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售要约或购买这些证券的要约邀请，在任何州或其他司法管辖区，在根据该州或其他司法管辖区的证券法进行注册或资格认定之前，如果此类要约、邀请或销售是非法的，则不得在这些州或其他司法管辖区销售这些证券。

About Tempest Therapeutics

关于Tempest Therapeutics

Tempest Therapeutics is a clinical-stage biotechnology company developing next-generation

Tempest Therapeutics 是一家临床阶段的生物技术公司，致力于开发下一代

in vivo

体内

CAR-T therapies for cancer and autoimmune disease. Tempest's lead product candidate, TPST-4003, combines a clinically supported dual-targeting CD19/BCMA CAR structure with an advanced CD7-targeting delivery system to support broad immune reset across multiple indications. Tempest envisions a world in which immune reset therapies bring safe, effective, and broadly accessible therapeutic options to patients in need.

用于癌症和自身免疫性疾病的CAR-T疗法。Tempest的核心候选产品TPST-4003将具有临床依据的CD19/BCMA双靶点CAR结构与先进的CD7靶向递送系统相结合，以支持在多种适应症中实现广泛的免疫重置。Tempest展望一个通过免疫重置疗法为有需要的患者提供安全、有效且广泛可及的治疗选择的世界。

For additional information, visit Tempest's website at .

如需更多信息，请访问 Tempest 网站：。

https://www.tempesttx.com

https://www.tempesttx.com

.

。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, concerning Tempest. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest, as well as assumptions made by, and information currently available to, management of Tempest.

本新闻稿包含前瞻性陈述（包括经修订的《1934年证券交易法》第21E条和经修订的《1933年证券法》第27A条所定义的前瞻性陈述），涉及Tempest公司。这些陈述可能讨论有关未来计划、趋势、事件、经营业绩或财务状况的目标、意图和预期，或其他方面，基于Tempest管理层当前的信念以及管理层所作的假设和目前可获得的信息。

Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'could', 'expect,' 'anticipate,' 'plan,' 'likely,' 'believe,' 'estimate,' 'project,' 'intend,' 'goal', 'suggest', 'target' and other similar expressions.

前瞻性陈述通常包括具有预测性质的陈述，这些陈述依赖于或提及未来事件或条件，并包含诸如“可能”、“将”、“应当”、“会”、“可以”、“预期”、“预计”、“计划”、“很可能”、“相信”、“估计”、“预测”、“打算”、“目标”、“建议”、“旨在”及其他类似表述。

All statements that are not historical facts are forward-looking statements, including but not limited to, statements regarding: the consummation of the offering and the satisfaction of customary closing conditions related to the private placement, the use of proceeds therefrom, the potential exercise of the warrants and the receipt of Stockholder Approval.

所有非历史事实的陈述均为前瞻性陈述，包括但不限于以下方面的陈述：本次发行的完成及与私募相关的惯例交割条件的满足、所得款项的使用、认股权证的潜在行使以及获得股东批准。

All forward-looking statements in this press release are based on Tempest's current expectations, estimates and projections about its industry as well as management's current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.

本新闻稿中的所有前瞻性陈述均基于Tempest截至今日对其行业的当前预期、估计和预测，以及管理层对未来的信念和期望。这些陈述受多种风险和不确定性的影响，可能导致实际结果与前述或暗示的前瞻性陈述存在重大且不利差异。

These risks and uncertainties include, but are not limited to the market and other conditions, Tempest's need for .

这些风险和不确定性包括但不限于市场及其他状况，以及 Tempest 对……的需求。

Investor Contacts:

投资者联系人：

Sylvia Wheeler

西尔维娅·惠勒

Wheelhouse Life Science Advisors

Wheelhouse 生命科学顾问公司

swheeler@wheelhouselsa.com

swheeler@wheelhouselsa.com

Aljanae Reynolds

阿尔贾内·雷诺兹

Wheelhouse Life Science Advisors

Wheelhouse 生命科学顾问

areynolds@wheelhouselsa.com

areynolds@wheelhouselsa.com